Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Sientra reports Q2 EPS (68c), consensus (43c) » 16:18
08/10/20
08/10
16:18
08/10/20
16:18
SIEN

Sientra

$4.24 /

+0.055 (+1.31%)

Reports Q2 revenue…

Reports Q2 revenue $12.4M, consensus $8.75M. Jeff Nugent, Sientra's Chairman and Chief Executive Officer, said, "While the COVID-19 pandemic has posed unprecedented challenges, we are encouraged by our performance through this stage of the recovery and our competitive position as we exited Q2. We are particularly encouraged by the durability of the demand for our OPUS(R) breast implants and tissue expanders, as well as the effectiveness of our Drive the Recovery initiatives as we continued to take share from our competitors through new account additions and further penetration of our existing customers. We also successfully transitioned our miraDry business to focus on high-margin, recurring bioTip sales and have seen utilization rates return to pre-COVID-19 levels in key geographic markets, including the United States, as we exited Q2."

ShowHide Related Items >><<
SIEN Sientra
$4.24 /

+0.055 (+1.31%)

SIEN Sientra
$4.24 /

+0.055 (+1.31%)

06/11/20 Maxim
Sientra price target raised to $8 from $5 at Maxim
03/12/20 Craig-Hallum
Sientra price target lowered to $9 from $14 at Craig-Hallum
03/12/20 SVB Leerink
Sientra price target lowered to $6.50 from $13 at SVB Leerink
03/12/20 Maxim
Sientra price target lowered to $8 from $12 at Maxim
SIEN Sientra
$4.24 /

+0.055 (+1.31%)

Hot Stocks
Spark Therapeutics appoints Gallia Levy as CMO » 08:31
08/10/20
08/10
08:31
08/10/20
08:31
RHHBY

Roche

$0.00 /

+ (+0.00%)

Spark Therapeutics…

Spark Therapeutics announced the appointment of Gallia Levy, M.D., Ph.D., as chief medical officer. Dr. Levy will be responsible for strategic and operational leadership across all functions in the product development lifecycle, including setting the global development strategy for current and future pipeline programs. Levy joins Spark Therapeutics from Genentech, also a member of the Roche Group, where she served as the Vice President and Global Head of the Rare Blood Disorders franchise in Product Development.

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
07/24/20 Credit Suisse
Credit Suisse backs Neutral on Roche after H1 results
07/24/20 UBS
Roche Q2 sales weak but recovery in June is evident, says UBS
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

Recommendations
Guardion Health Sciences FDA approval landmark event, says Canaccord » 08:19
08/10/20
08/10
08:19
08/10/20
08:19
GH

Guardant Health

$85.79 /

+2.99 (+3.61%)

Canaccord analyst Mark…

Canaccord analyst Mark Massaro said the FDA approval for Guardant360 for comprehensive genomic profiling in patients with solid tumor cancer, is a landmark event in precision medicine. He expects the FDA approval to serve as a major catalyst to drive adoption from medical oncologists that were skeptical of its performance versus standard-of-care tissue based tests. Massaro reiterated his Buy rating and $125 price target on Guardant shares.

ShowHide Related Items >><<
GH Guardant Health
$85.79 /

+2.99 (+3.61%)

GH Guardant Health
$85.79 /

+2.99 (+3.61%)

06/12/20
Fly Intel: Top five analyst initiations
06/12/20 BTIG
BTIG starts genomic profiling test 'pioneer' Guardant Health at Buy
06/11/20 BTIG
Guardant Health initiated with a Buy at BTIG
05/08/20 Citi
Guardant Health price target raised to $110 from $100 at Citi
GH Guardant Health
$85.79 /

+2.99 (+3.61%)

  • 02
    Jun
GH Guardant Health
$85.79 /

+2.99 (+3.61%)

Hot Stocks
Genentech says etrolizumab trial met one primary endpoint, failed to meet other » 05:14
08/10/20
08/10
05:14
08/10/20
05:14
RHHBY

Roche

$0.00 /

+ (+0.00%)

Genentech, a member of…

Genentech, a member of the Roche Group, announced topline results from its Phase III study program evaluating the investigational medicine etrolizumab in people with moderately to severely active ulcerative colitis. Genentech said in a release, "Mixed results were seen in studies evaluating etrolizumab as an induction therapy, and both studies evaluating etrolizumab as a maintenance therapy failed to meet their primary endpoints, showing no significant difference in the proportion of people achieving remission with subcutaneous etrolizumab versus placebo. In the HIBISCUS I induction study, in people without prior anti-tumor necrosis factor (anti-TNF) treatment, etrolizumab met the primary endpoint. In contrast, the HIBISCUS II induction study, which also included people without prior anti-TNF treatment, did not meet its primary endpoint. In the HICKORY study, in people with prior anti-TNF treatment, etrolizumab met the primary endpoint at induction but not at maintenance. In the LAUREL maintenance study in people without prior anti-TNF treatment, etrolizumab failed to meet its primary endpoint. The safety profile of etrolizumab was consistent with previous studies and no major safety issues were identified in the four Phase III clinical trials reported to date. Further analyses of the data, including secondary endpoints, are ongoing and will be submitted for presentation at upcoming medical meetings. Etrolizumab continues to be studied as an investigational induction and maintenance treatment in people with moderately to severely active Crohn's disease with and without prior anti-TNF treatment in a global Phase III study (BERGAMOT) and open-label extension and safety monitoring study (JUNIPER), involving more than 1,100 people with Crohn's disease. In addition, Genentech is studying other investigational medicines in inflammatory bowel diseases and is committed to further understanding this disease."

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
07/24/20 Credit Suisse
Credit Suisse backs Neutral on Roche after H1 results
07/24/20 UBS
Roche Q2 sales weak but recovery in June is evident, says UBS
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

Saturday
On The Fly
Week in review: How Trump's policies moved stocks » 07:32
08/08/20
08/08
07:32
08/08/20
07:32
TCEHY

Tencent

$0.00 /

+ (+0.00%)

, MSFT

Microsoft

$212.45 /

-3.87 (-1.79%)

, AZN

AstraZeneca

$55.40 /

-0.8 (-1.42%)

, BMY

Bristol-Myers

$61.03 /

-0.27 (-0.44%)

, LLY

Eli Lilly

$152.89 /

+0.01 (+0.01%)

, GSK

GlaxoSmithKline

$40.79 /

-0.185 (-0.45%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, KODK

Eastman Kodak

$14.88 /

-1.195 (-7.43%)

, AA

Alcoa

$14.67 /

-0.22 (-1.48%)

, CENX

Century Aluminum

$10.53 /

-0.06 (-0.57%)

, KALU

Kaiser Aluminum

$66.81 /

+0.49 (+0.74%)

, ARNC

Arconic

$19.94 /

-0.395 (-1.94%)

, FB

Facebook

$268.52 /

+3.295 (+1.24%)

, TWTR

Twitter

$37.14 /

-0.55 (-1.46%)

Catch up on the top…

Open Full Text

ShowHide Related Items >><<
TWTR Twitter
$37.14 /

-0.55 (-1.46%)

TCEHY Tencent
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MSFT Microsoft
$212.45 /

-3.87 (-1.79%)

LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

KODK Eastman Kodak
$14.88 /

-1.195 (-7.43%)

KALU Kaiser Aluminum
$66.81 /

+0.49 (+0.74%)

GSK GlaxoSmithKline
$40.79 /

-0.185 (-0.45%)

FB Facebook
$268.52 /

+3.295 (+1.24%)

CENX Century Aluminum
$10.53 /

-0.06 (-0.57%)

BMY Bristol-Myers
$61.03 /

-0.27 (-0.44%)

AZN AstraZeneca
$55.40 /

-0.8 (-1.42%)

ARNC Arconic
$19.94 /

-0.395 (-1.94%)

AA Alcoa
$14.67 /

-0.22 (-1.48%)

TCEHY Tencent
$0.00 /

+ (+0.00%)

08/03/20 Morgan Stanley
Sohu.com named a Research Tactical Idea at Morgan Stanley
07/27/20 Barclays
Tencent price target raised to $75 from $63 at Barclays
07/14/20 Citi
Tencent price target raised to HK$649 from HK$541 at Citi
07/08/20 Mizuho
Tencent price target raised to HK$475 from HK$410 at Mizuho
MSFT Microsoft
$212.45 /

-3.87 (-1.79%)

08/07/20 DA Davidson
Datadog price target raised to $80 from $52 at DA Davidson
08/05/20 Morgan Stanley
Morgan Stanley says TikTok US operations could be 'compelling' fit for Microsoft
08/04/20 Wedbush
Wedbush sees 75%-80% chance of Microsoft buying TikTok's U.S. operations
08/04/20 Oppenheimer
TikTok presents 'unique opportunity' for Microsoft, says Oppenheimer
AZN AstraZeneca
$55.40 /

-0.8 (-1.42%)

08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/31/20 Barclays
Barclays backs Overweight on AstraZeneca after Q2 results
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
BMY Bristol-Myers
$61.03 /

-0.27 (-0.44%)

08/06/20 Citi
Investors can refocus on Bristol-Myers story after Eliquis win, says Citi
07/28/20 Mizuho
Wait for Bristol-Myers' bb2121 submission making some 'nervous,' says Mizuho
07/28/20
Fly Intel: Top five analyst initiations
07/28/20 Raymond James
Bristol-Myers initiated with an Outperform at Raymond James
LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

07/31/20 Barclays
Eli Lilly earnings selloff 'meaningful over-reaction,' says Barclays
07/15/20 H.C. Wainwright
Blueprint Medicines price target raised to $110 from $66 at H.C. Wainwright
07/14/20 Baird
Blueprint Medicines price target raised to $100 from $90 at Baird
07/14/20 Raymond James
Blueprint Medicines price target raised to $106 from $95 at Raymond James
GSK GlaxoSmithKline
$40.79 /

-0.185 (-0.45%)

07/31/20 Barclays
Barclays backs Underweight on GSK after 'challenging' Q2
07/30/20 Roth Capital
Roth Capital bullish on Ideaya as GSK highlights synthetic lethality pipeline
07/13/20 UBS
UBS reiterates Buy on GSK as FDA belantamab docs are out
07/13/20 JPMorgan
Ideaya upgraded to Overweight on recent pullback at JPMorgan
RHHBY Roche
$0.00 /

+ (+0.00%)

07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
07/24/20 Credit Suisse
Credit Suisse backs Neutral on Roche after H1 results
07/24/20 UBS
Roche Q2 sales weak but recovery in June is evident, says UBS
KODK Eastman Kodak
$14.88 /

-1.195 (-7.43%)

AA Alcoa
$14.67 /

-0.22 (-1.48%)

07/16/20 B. Riley FBR
Alcoa price target raised to $11 from $9 at B. Riley FBR
06/16/20
Fly Intel: Top five analyst downgrades
06/16/20 Deutsche Bank
Alcoa downgraded to Hold with $10 price target at Deutsche Bank
06/15/20 Deutsche Bank
Alcoa downgraded to Hold from Buy at Deutsche Bank
CENX Century Aluminum
$10.53 /

-0.06 (-0.57%)

06/25/20 BMO Capital
Century Aluminum downgraded to Market Perform from Outperform at BMO Capital
06/09/20 B. Riley FBR
B. Riley FBR downgrades Contura Energy after liquidity stress test
03/24/20 B. Riley FBR
Century Aluminum downgraded to Neutral from Buy at B. Riley FBR
12/20/19 B. Riley FBR
Alcoa price target lowered to $25 from $28 at B. Riley FBR
KALU Kaiser Aluminum
$66.81 /

+0.49 (+0.74%)

01/16/20 Benchmark
Kaiser Aluminum initiated with a Hold at Benchmark
08/08/19 Goldman Sachs
Kaiser Aluminum upgraded to Neutral from Sell at Goldman Sachs
ARNC Arconic
$19.94 /

-0.395 (-1.94%)

05/20/20
Fly Intel: Top five analyst initiations
05/20/20 Credit Suisse
Arconic initiated with an Outperform at Credit Suisse
04/01/20 Cowen
Howmet Aerospace price target lowered to $17 from $23 at Cowen
03/20/20 Barclays
Arconic downgraded to Equal Weight from Overweight at Barclays
FB Facebook
$268.52 /

+3.295 (+1.24%)

08/05/20 HSBC
HSBC bumps up Facebook target to $195, maintains Reduce rating
08/04/20 Argus
Facebook price target raised to $300 from $270 at Argus
08/03/20 Wedbush
Wedbush sees a TikTok deal as big bet from Microsoft on social media space
08/03/20 DA Davidson
Pinterest price target raised to $28 from $19 at DA Davidson
TWTR Twitter
$37.14 /

-0.55 (-1.46%)

07/28/20 Morgan Stanley
Morgan Stanley lowers near-term, long-term forecasts for Roku
07/24/20 Truist
Twitter price target raised to $40 from $32 at SunTrust
07/24/20 Argus
Twitter price target raised to $46 from $40 at Argus
07/24/20 Canaccord
Twitter price target raised to $40 from $32 at Canaccord
TWTR Twitter
$37.14 /

-0.55 (-1.46%)

TCEHY Tencent
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MSFT Microsoft
$212.45 /

-3.87 (-1.79%)

LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

KALU Kaiser Aluminum
$66.81 /

+0.49 (+0.74%)

GSK GlaxoSmithKline
$40.79 /

-0.185 (-0.45%)

FB Facebook
$268.52 /

+3.295 (+1.24%)

CENX Century Aluminum
$10.53 /

-0.06 (-0.57%)

BMY Bristol-Myers
$61.03 /

-0.27 (-0.44%)

AZN AstraZeneca
$55.40 /

-0.8 (-1.42%)

ARNC Arconic
$19.94 /

-0.395 (-1.94%)

AA Alcoa
$14.67 /

-0.22 (-1.48%)

TWTR Twitter
$37.14 /

-0.55 (-1.46%)

TCEHY Tencent
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MSFT Microsoft
$212.45 /

-3.87 (-1.79%)

LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

KODK Eastman Kodak
$14.88 /

-1.195 (-7.43%)

GSK GlaxoSmithKline
$40.79 /

-0.185 (-0.45%)

FB Facebook
$268.52 /

+3.295 (+1.24%)

BMY Bristol-Myers
$61.03 /

-0.27 (-0.44%)

AZN AstraZeneca
$55.40 /

-0.8 (-1.42%)

AA Alcoa
$14.67 /

-0.22 (-1.48%)

TWTR Twitter
$37.14 /

-0.55 (-1.46%)

TCEHY Tencent
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MSFT Microsoft
$212.45 /

-3.87 (-1.79%)

LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

GSK GlaxoSmithKline
$40.79 /

-0.185 (-0.45%)

FB Facebook
$268.52 /

+3.295 (+1.24%)

BMY Bristol-Myers
$61.03 /

-0.27 (-0.44%)

AZN AstraZeneca
$55.40 /

-0.8 (-1.42%)

ARNC Arconic
$19.94 /

-0.395 (-1.94%)

AA Alcoa
$14.67 /

-0.22 (-1.48%)

TWTR Twitter
$37.14 /

-0.55 (-1.46%)

MSFT Microsoft
$212.45 /

-3.87 (-1.79%)

LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

KODK Eastman Kodak
$14.88 /

-1.195 (-7.43%)

GSK GlaxoSmithKline
$40.79 /

-0.185 (-0.45%)

FB Facebook
$268.52 /

+3.295 (+1.24%)

BMY Bristol-Myers
$61.03 /

-0.27 (-0.44%)

AZN AstraZeneca
$55.40 /

-0.8 (-1.42%)

ARNC Arconic
$19.94 /

-0.395 (-1.94%)

AA Alcoa
$14.67 /

-0.22 (-1.48%)

MSFT Microsoft
$212.45 /

-3.87 (-1.79%)

Friday
Hot Stocks
Guardant Health announces FDA approval for Guardant360 CDx for CGP » 14:28
08/07/20
08/07
14:28
08/07/20
14:28
GH

Guardant Health

$82.50 /

-0.3 (-0.36%)

Guardant Health announces…

Guardant Health announces that the U.S. Food and Drug Administration has approved Guardant360 CDx for tumor mutation profiling, also known as comprehensive genomic profiling, or CGP, in patients with any solid malignant neoplasm. The Guardant360 CDx is also approved as a companion diagnostic to identify non-small cell lung cancer patients with epidermal growth factor receptor alterations who may benefit from treatment with Tagrisso. "Guardant360 CDx offers patients and clinicians a simple, faster blood test to help inform personalized treatment options," the company said. "The FDA approval of Guardant360 CDx is a landmark decision, demonstrating the value liquid biopsy delivers to oncologists and more importantly, the patients they treat. Traditional tissue biopsy-based tumor profiling, which is often invasive and has longer turnaround times, can contribute to delays in starting treatment and possibly suboptimal therapy. We applaud the FDA for their collaborative review process and for approving the first comprehensive genomic profiling liquid biopsy test. We are confident that our FDA approval will help accelerate wider adoption of guideline-recommended genomic profiling, increase the number of advanced cancer patients who receive potentially life-changing treatments, and pave the way for new companion diagnostic developments for the Guardant360 CDx," added Guardant Health CEO Helmy Eltoukhy.

ShowHide Related Items >><<
GH Guardant Health
$82.50 /

-0.3 (-0.36%)

GH Guardant Health
$82.50 /

-0.3 (-0.36%)

06/12/20
Fly Intel: Top five analyst initiations
06/12/20 BTIG
BTIG starts genomic profiling test 'pioneer' Guardant Health at Buy
06/11/20 BTIG
Guardant Health initiated with a Buy at BTIG
05/08/20 Citi
Guardant Health price target raised to $110 from $100 at Citi
GH Guardant Health
$82.50 /

-0.3 (-0.36%)

  • 02
    Jun
GH Guardant Health
$82.50 /

-0.3 (-0.36%)

Hot Stocks
Guardant Health halted, news pending  14:22
08/07/20
08/07
14:22
08/07/20
14:22
GH

Guardant Health

$82.39 /

-0.41 (-0.50%)

 
ShowHide Related Items >><<
GH Guardant Health
$82.39 /

-0.41 (-0.50%)

GH Guardant Health
$82.39 /

-0.41 (-0.50%)

06/12/20
Fly Intel: Top five analyst initiations
06/12/20 BTIG
BTIG starts genomic profiling test 'pioneer' Guardant Health at Buy
06/11/20 BTIG
Guardant Health initiated with a Buy at BTIG
05/08/20 Citi
Guardant Health price target raised to $110 from $100 at Citi
GH Guardant Health
$82.39 /

-0.41 (-0.50%)

  • 02
    Jun
GH Guardant Health
$82.39 /

-0.41 (-0.50%)

Hot Stocks
PTC wins FDA approval of spinal muscular atrophy treatment Evrysdi » 13:58
08/07/20
08/07
13:58
08/07/20
13:58
PTCT

PTC Therapeutics

$50.33 /

+3.31 (+7.04%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

PTC Therapeutics (PTCT)…

PTC Therapeutics (PTCT) announced that the Food and Drug Administration has approved Evrysdi, the first at-home, orally administered treatment for spinal muscular atrophy in adults and children two months and older. Evrysdi will be available in the United States within two weeks for direct delivery to patients' homes through Accredo Health Group, an Express Scripts specialty pharmacy, PTC noted. Evrysdi will be marketed in the United States by Genentech, a unit of Roche Group (RHHBY). Outside the United States, Roche holds global commercialization rights to risdiplam. Shares of PTC Therapeutics halted for trade up 7% to $50.35.

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

PTCT PTC Therapeutics
$50.33 /

+3.31 (+7.04%)

PTCT PTC Therapeutics
$50.33 /

+3.31 (+7.04%)

07/20/20 Credit Suisse
Credit Suisse downgrades PTC Therapeutics after risdiplam royalty deal
07/20/20 Credit Suisse
PTC Therapeutics downgraded to Neutral from Outperform at Credit Suisse
07/20/20 Truist
PTC Therapeutics price target raised to $86 from $75 at SunTrust
06/09/20 Citi
PTC Therapeutics pipeline not fully appreciated, says Citi
RHHBY Roche
$0.00 /

+ (+0.00%)

07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
07/24/20 Credit Suisse
Credit Suisse backs Neutral on Roche after H1 results
07/24/20 UBS
Roche Q2 sales weak but recovery in June is evident, says UBS
RHHBY Roche
$0.00 /

+ (+0.00%)

PTCT PTC Therapeutics
$50.33 /

+3.31 (+7.04%)

  • 18
    Sep
RHHBY Roche
$0.00 /

+ (+0.00%)

PTCT PTC Therapeutics
$50.33 /

+3.31 (+7.04%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PTCT PTC Therapeutics
$50.33 /

+3.31 (+7.04%)

Hot Stocks
Roche announces FDA approval of Evrysdi for Spinal Muscular Atrophy treatment » 13:50
08/07/20
08/07
13:50
08/07/20
13:50
PTCT

PTC Therapeutics

$50.19 /

+3.17 (+6.74%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, ESRX

Express Scripts

$92.49 /

+ (+0.00%)

Genentech, a member of…

Genentech, a member of the Roche Group (RHHBY), announced that the U.S. Food and Drug Administration has approved Evrysdi, or risdiplam, for treatment of spinal muscular atrophy, or SMA, in adults and children 2 months of age and older. A liquid medicine, Evrysdi is administered daily at home by mouth or feeding tube. Evrysdi is designed to treat SMA by increasing production of the survival of motor neuron protein, which is found throughout the body and is critical for maintaining healthy motor neurons and movement, the company said. Genentech leads the clinical development of Evrysdi as part of a collaboration with the SMA Foundation and PTC Therapeutics (PTCT). Evrysdi will be available in the United States within two weeks for direct delivery to patients' homes through Accredo Health Group, an Express Scripts (ESRX) specialty pharmacy.

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

PTCT PTC Therapeutics
$50.19 /

+3.17 (+6.74%)

ESRX Express Scripts
$92.49 /

+ (+0.00%)

PTCT PTC Therapeutics
$50.19 /

+3.17 (+6.74%)

07/20/20 Credit Suisse
Credit Suisse downgrades PTC Therapeutics after risdiplam royalty deal
07/20/20 Credit Suisse
PTC Therapeutics downgraded to Neutral from Outperform at Credit Suisse
07/20/20 Truist
PTC Therapeutics price target raised to $86 from $75 at SunTrust
06/09/20 Citi
PTC Therapeutics pipeline not fully appreciated, says Citi
RHHBY Roche
$0.00 /

+ (+0.00%)

07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
07/24/20 Credit Suisse
Credit Suisse backs Neutral on Roche after H1 results
07/24/20 UBS
Roche Q2 sales weak but recovery in June is evident, says UBS
ESRX Express Scripts
$92.49 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PTCT PTC Therapeutics
$50.19 /

+3.17 (+6.74%)

  • 18
    Sep
RHHBY Roche
$0.00 /

+ (+0.00%)

PTCT PTC Therapeutics
$50.19 /

+3.17 (+6.74%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PTCT PTC Therapeutics
$50.19 /

+3.17 (+6.74%)

Hot Stocks
Roche announces FDA approval of Evrysdi for Spinal Muscular Atrophy treatment  13:48
08/07/20
08/07
13:48
08/07/20
13:48
PTCT

PTC Therapeutics

$50.10 /

+3.08 (+6.55%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

 
ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

PTCT PTC Therapeutics
$50.10 /

+3.08 (+6.55%)

PTCT PTC Therapeutics
$50.10 /

+3.08 (+6.55%)

07/20/20 Credit Suisse
Credit Suisse downgrades PTC Therapeutics after risdiplam royalty deal
07/20/20 Credit Suisse
PTC Therapeutics downgraded to Neutral from Outperform at Credit Suisse
07/20/20 Truist
PTC Therapeutics price target raised to $86 from $75 at SunTrust
06/09/20 Citi
PTC Therapeutics pipeline not fully appreciated, says Citi
RHHBY Roche
$0.00 /

+ (+0.00%)

07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
07/24/20 Credit Suisse
Credit Suisse backs Neutral on Roche after H1 results
07/24/20 UBS
Roche Q2 sales weak but recovery in June is evident, says UBS
RHHBY Roche
$0.00 /

+ (+0.00%)

PTCT PTC Therapeutics
$50.10 /

+3.08 (+6.55%)

  • 18
    Sep
RHHBY Roche
$0.00 /

+ (+0.00%)

PTCT PTC Therapeutics
$50.10 /

+3.08 (+6.55%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PTCT PTC Therapeutics
$50.10 /

+3.08 (+6.55%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.